Celldex Therapeutics Inc. (CLDX)
Celldex Therapeutics Inc. (CLDX) Stock Price, Analysis & Data
| Precio de compra | 35.39 |
| Capitalización de mercado | 3.28B |
| Ingresos (TTM) | 158K |
| Beneficio neto (TTM) | -300.55M |
| Beta | 0.84 |
| EPS (TTM) | -4.35 |
| Ratio PER (TTM) | n/a |
| Adelante PE | -10.04 |
| P/B (TTM) | 4.59 |
| P/S (TTM) | 20770.57 |
| Earnings Date | Nov 9, 2026 |
| Precio de venta | 47.93 |
| Volumen | 849,364 |
| Volumen medio (20D) | 1,028,190 |
| Abierto | 42.34 |
| Anterior Cerrar | 42.61 |
| Rango del día | 40.88 - 42.34 |
| Rango de 52 semanas | 20.37 - 45.14 |
| analista | n/a |
| Precio objetivo | n/a |
| Dividendos | n/a |
| Fecha ex dividendo | n/a |
Acerca de CLDX
Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic antibodies for patients with severe inflammatory, allergic, autoimmune, and other diseases. The company's drug candidates include monoclonal and bispecific antibodies designed to address mast cell mediated diseases for which available treatments are inadequate. It develops clinical programs, including Barzolvolimab (CDX-0159), a monoclonal antibody that spe...
Desempeño financiero
En 2025, los ingresos de Celldex Therapeutics fueron 1.54M, una disminución de -77.99% en comparación con 7.02M del año anterior. Las ganancias fueron -258.76M, un aumento de 63.91%.
Estados financierosSorpresa de resultados
Los analistas proyectan ingresos de ... Actualizar
1 semana hace · Simply Wall St.
Celldex Therapeutics (CLDX) Could Be 130% Undervalued After Second Quarter ResultsCelldex Therapeutics (CLDX) released its second quarter 2026 results on 6 August, reporting very limited revenue and a wider net loss. This places the stock’s recent strength in sharper focus for inve...
1 semana hace · Simply Wall St.
Celldex Therapeutics (CLDX) Stock Trades At A Premium Despite A 102% ReturnCelldex Therapeutics stock has more than doubled over the past year, yet its broader valuation checks lean expensive rather than cheap, which raises questions about how much of its pipeline story is a...
1 semana hace · Simply Wall St.
What Is Celldex Therapeutics (CLDX) Signaling With Its Mixed Pipeline Update?Celldex Therapeutics (NasdaqCM:CLDX) reported updated clinical pipeline data, including positive Phase 1 results for bispecific antibody CDX-622. The company outlined progress on ongoing Phase 3 studi...
